Interpace Pharma Solutions (IPS) provides laboratory services supporting clinical trials and advanced diagnostic development across immuno-oncology, hematology, and solid tumors. Our scientific, medical, and regulatory experts help our biopharma and diagnostic clients accelerate their clinical development programs. Through our extensive technology portfolio and agile approach, we provide a broad suite of applications in support of our industry partners.
Interpace Pharma Solutions offers full molecular diagnostics capabilities utilizing various platforms to accommodate a variety of analyses. Its state-of-the-art molecular laboratory is technology-agnostic and equipped with the most innovative next-generation sequencing (NGS) and genotyping platforms.
We are transforming global drug development with our comprehensive suite of molecular diagnostic solutions that will help identify more qualified target populations for clinical studies and optimize the safety and efficacy of therapeutic compounds. The result is an overall improvement in Return on Investment, an important consideration in the landscape of escalating drug discovery and development costs.
We are a certified services provider for various companies such as Thermo Fisher, Invitae® (ArcherDx), NanoString® and offer full NGS capabilities with both Illumina® and Thermo Fisher Platforms, providing a mix of proprietary panels and off-the-shelf assays.
Pharma Solutions comprehensive menu of validated assays is ready for direct use in your oncology and non-oncology programs.
Development and Label Expansion
All of our expression analyses are available for integration into clinical studies. Custom assay development and validation services are offered to address client-specific requests. Pharma Solutions applies rigorous quality standards, including GLP and CLIA, to all studies in order to ensure the highest quality data is generated and reported. We are able to quantify gene expression in a broad spectrum of tissue samples, including formalin fixed paraffin embedded (FFPE) tissues specimens.
Comprehensive Profiling for Any Demand
The adoption of NGS in cancer research and clinical trials has led to a deeper understanding of tumor biology. One of the major challenges in diagnosing hematological and solid tumor cancers is the high degree of tumor heterogeneity. Mutations that have critical clinical implications may only be present in very low levels, making detection of these mutations difficult. Detection of such mutations is especially important in hematological and solid tumor malignancies, where tumors show a great deal of heterogeneity and accurate prognosis is essential to identifying patient with more aggressive disease. NGS helps respond to these challenges by providing a comprehensive view of the tumor’s genomic profile. Importantly, NGS can detect multiple mutations present at very low levels within the tumor.
NGS methods for genome, exome, and transcriptome analysis are leading to new genomic insights and paving the way for establishing the foundation necessary to drive the long-term goals of personalized medicine. With the advancements in NGS technology, international projects such as the International Cancer Genome Consortium, and the economies of scale, NGS has become a powerful and clinically relevant tool.
Pharma Solutions offers an extensive suite of NGS services to meet any demand, including hypothesis-free studies, turn-key solutions with actionable content for diagnosis/prognosis/risk stratification, as well as fully customizable panels built to specification with the help of our highly trained and experienced team of bioinformaticists and scientists.